Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - fentanyl citrate, quantity: 0.785 mg/ml (equivalent: fentanyl, qty 0.5 mg/ml) - spray, nasal - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate dihydrate; purified water - instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - fentanyl citrate, quantity: 0.785 mg/ml (equivalent: fentanyl, qty 0.5 mg/ml) - spray, nasal - excipient ingredients: monobasic sodium phosphate dihydrate; dibasic sodium phosphate dihydrate; purified water - instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fentanyl citrate, quantity: 785 microgram (equivalent: fentanyl, qty 500 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections - short duration analgesia during premedication, induction and maintenance of anaesthesia, and in the immediate postoperative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic premedication for the induction of anaesthesia, and as an adjunct in the maintanance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fentanyl citrate, quantity: 157 microgram (equivalent: fentanyl, qty 100 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections - short duration analgesia during premedication, induction and maintenance of anaesthesia, and in the immediate postoperative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic premedication for the induction of anaesthesia, and as an adjunct in the maintanance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fentanyl citrate, quantity: 392.5 microgram (equivalent: fentanyl, qty 250 microgram) - injection, solution - excipient ingredients: water for injections; sodium chloride - short duration analgesia during premedication, induction and maintenance of anaesthesia, and in the immediate postoperative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic premedication for the induction of anaesthesia, and as an adjunct in the maintanance of general and regional anaesthesia.

Israel - English - Ministry of Health

pharma medis - fentanyl as citrate - solution for injection - fentanyl as citrate 0.05 mg/ml - fentanyl - fentanyl - for analgesic action of short duration during anesthtic periods (premedication dinduction and maintenance) and in the immediate postoperative period as need arises. as a narcotic analgesic supplement in general or regional anesthesia. for administration with neuroleptics (such as droperidol) as an anesthetic premedication for the induction of anesthesia and as an adjunct in the maintenance of general or regional anesthesia. for use as an anesthetic agent with oxygen in selected high-risk patients (open heart surgery or certain neurological or orthopedic procedures). by the epidural route for the postoperative management of pain following general surgical procedures and cesarean sections and as adjunct to general anesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 2.1 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 16.8 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 4.2 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 8.4 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.